HBP — Helix Biopharma Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapMomentum Trap
- CA$41.00m
- CA$38.18m
Annual income statement for Helix Biopharma, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2018 July 31st | 2019 July 31st | 2020 July 31st | 2021 July 31st | 2022 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.55 | 7.49 | 8.62 | 9.13 | 6.04 |
| Operating Profit | -8.55 | -7.49 | -8.62 | -9.13 | -6.04 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.63 | -7.53 | -8.56 | -9.57 | -6.56 |
| Net Income After Taxes | -8.63 | -7.53 | -8.56 | -9.57 | -6.56 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -8.63 | -7.53 | -8.98 | -8.04 | -6.56 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.63 | -7.53 | -8.98 | -8.04 | -6.56 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.086 | -0.071 | -0.066 | -0.069 | -0.044 |